Deep search
Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent

News

Trump admin launching pilot program to cover Ozempic

Newsweek on MSN · 1d
Medicare update: Trump admin launching pilot program to cover Ozempic
Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.
Gizmodo · 1d
Feds Launch Experiment to Have Medicare Cover GLP-1 Weight Loss Drugs
The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity medications.
ConsumerAffairs · 1d
Report: Trump Administration planning test of covering GLP-1 drugs through Medicare, Medicaid
Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The Washington Post reports.
News Nation on MSN1d

GLP-1 drugs like Ozempic have ‘surprising’ positive effects: Doctor

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...
NBC DFW6mon

Ozempic is in the next round of Medicare drug price negotiations ...

How much Medicare spent on the drugs Among the 10 drugs listed, Medicare Part D spent the most on Ozempic, Rybelsus and Wegovy, at $14.43 billion, according to a CMS fact sheet on Friday.
1d

A Medicare experiment could change who gets Ozempic

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy